Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Lupin Group’s Kyowa Sees Japan-India Collaboration as Key to Survival: Pres.
April 1, 2015
-
ACADEMIA CRPC Drugs Xtandi, Zytiga Neck-and-Neck in Key Opinion Leader Poll
April 1, 2015
-
BUSINESS Fujifilm to Buy US iPS Cell Manufacturer Cellular Dynamics
March 31, 2015
-
REGULATORY Otani, Ex-Number 2 at MHLW, Tapped as Aide to Chief of AMED
March 30, 2015
-
BUSINESS Pfizer Looking for Drug Discovery Partnerships with Domestic Drug Makers
March 30, 2015
-
REGULATORY Nonpartisan Group Launched to Push Biosimilar Use, Lawmaker-Sponsored Bill Eyed
March 27, 2015
-
BUSINESS Sovaldi, Oral, Interferon-Free Treatment, Approved for Chronic HCV Infection in Japan: Gilead Sciences
March 27, 2015
-
ORGANIZATION Applying Uniform Pricing Rule to Unprofitable but Essential Drugs Difficult: Kenporen Veep
March 26, 2015
-
BUSINESS 3-Bracket Pricing Rule for Generics Should Be Defended: Sawai Chairman
March 25, 2015
-
BUSINESS Takeda to Collaborate with ImmunoGen for ADC Technology
March 25, 2015
-
BUSINESS AZ Looks to Lead Industry in Immuno-Oncology Arena: Oncology Head
March 24, 2015
-
INTERVIEW Takeda Aims to Return to Growth Track in FY2016, Sales Head Confident in Takecab
March 23, 2015
-
BUSINESS Amgen Astellas Seeks Japan Approval of PCSK9 Inhibitor
March 23, 2015
-
ORGANIZATION FPMAJ Renews Call for Changing NHI Pricing Rules for Unprofitable Drugs with Great Medical Needs
March 20, 2015
-
REGULATORY Chuikyo OKs Quantitative Premium Calculation for Operating Profit Rates
March 19, 2015
-
BUSINESS MSD Revving Up Detailing on Rotavirus, Hepatitis B Vaccines, Eyes Public Immunization Program
March 18, 2015
-
ACADEMIA Researcher Has High Hopes for Immunotherapies as Fourth Pillar of Cancer Treatment
March 17, 2015
-
BUSINESS Takecab Surged to Top Spot in January Anterio Ranking
March 16, 2015
-
REGULATORY Prime Minister Abe Indicates the Need to Promote the Use of Biosimilars
March 16, 2015
-
REGULATORY PMDA Plans to Introduce Full Scale “Patient ADR Reporting System” by FY2018
March 13, 2015
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…